Rates of CR/CRi and survival varied by WHO and ICC classification groups, with the best outcomes in AML with NPM1 mutations (CR/CRi, 78%; median OS, 22 months) and the poorest with MECOMr (CR/CRi, 17%; median OS, 4 months) and TP53 mutations (CR/CRi, 49%; median OS, 8 months; supplemental Figure 6A,C). Here, NPM1 is linked to intrahepatic cholangiocarcinoma.